The JAK inhibitor baricitinib (Olumiant) has been listed on the PBS from 1 September for patients with rheumatoid arthritis (RA).

The once daily tablet drug is available as an Authority required item for adult patients with moderate to severe active RA who have responded inadequately, or who are intolerant, to one or more DMARDs.

The listing was welcomed by Professor Kevin Pile, rheumatologist, at Campbelltown Hospital, NSW, who said almost half of patients with RA do not achieve remission with current therapies.

“This listing offers an additional treatment option for those living with this condition, who, despite receiving treatment, are still suffering from symptoms,” he said in a statement released by the manufacturer Eli Lilly.